On March 13, 2023 Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) reported additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).1 (Press release, Telix Pharmaceuticals, MAR 13, 2023, View Source [SID1234628604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The results were featured in a "Game Changing" oral session delivered by Professor Dr. Peter Mulders from Radboud University Medical Centre (Netherlands), a ZIRCON Principal Investigator, at the 38th Annual European Association of Urology (EAU) Congress, on Saturday, 11 March 2023.

Game Changing sessions are reserved for Phase III trials or other developments that the EAU’s Scientific Congress Office believes will have a large impact on daily practice.

New data presented:

TLX250-CDx demonstrated a high degree of consistency between readers with a very high sensitivity (85.5%) and specificity (87.0%) overall, and 85.5% / 89.5% for small masses (<4cm), confirming optimal SUVmax thresholds for image interpretation;
The correlation of CAIX expression on histology with imaging results.
Professor Dr. Peter Mulders commented, "I’m delighted to be at EAU, the leading urological event in Europe, sharing further detailed results from Telix’s Phase III ZIRCON study with the medical community. New data reinforces the clinical potential of this investigational agent, even in small renal masses which are most prevalent and present the highest diagnostic challenge, with remarkable consistency across readers. On behalf of Telix, I’d like to thank all the European sites and patients for their participation in this ground-breaking study."

Telix is in the process of establishing expanded access studies and supporting named patient programs for TLX250-CDx in the United States and Europe.

On March 13, 2023 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, reported that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank ("SVB") due to liquidity concerns (Press release, CNS Pharmaceuticals, MAR 13, 2023, View Source [SID1234628603]). The Company does not hold any deposits or investments at SVB.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 13, 2023 On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) reported a strategic partnership to advance cell and gene therapy R&D pipelines (Press release, Porton Advanced Solutions, MAR 13, 2023, View Source [SID1234628602]). The partnership aims to accelerate the development of T-cell therapies for tumors and autoimmune diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As an end-to-end gene and cell therapy service CDMO, Porton Advanced provides comprehensive solutions covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy. Bennu Biotherapeutics is focused on developing T-cell therapies to address T-cell exhaustion, offering TIL, TCR-T, and Treg therapy for solid tumors and autoimmune diseases. Under this strategic agreement, Porton Advanced will provide CDMO services for multiple pipelines for gene and cell therapy, including plasmids, virus, TIL, TCR-T, and Treg, to Bennu Biotherapeutics.

"We are pleased to collaborate with Bennu Biotherapeutics, which focuses on the development of innovative therapies for tumors and autoimmune diseases. Through our end-to-end Cell and Gene Therapy CDMO, Porton Advanced aims to help Bennu Biotherapeutics develop multiple pipelines for cell therapy products, accelerate the development of innovative drugs such as TIL, and bring these beneficial drugs to market as soon as possible," said Dr. Yangzhou Wang, CEO of Proton Advanced.

Ms. Zhao Ping, Co-founder and CEO of Bennu Biotherapeutics, said, "We can advance our process development and production by utilizing the advanced process development technologies provided by Porton Advanced. Through this strategic cooperation, we can accelerate the development of our process development platforms, enhancing our strength and market competitiveness. Both companies will continue to explore and innovate, giving full play to their advantages and making the biotechnology industry prosper in rapid development."

On March 13, 2023 Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to prevent infectious diseases and treat cancer, reported its intellectual property position reinforcement in mRNA vaccine technology with the issue of U.S. Patent 11,596,685 by the United States Patent and Trademark Office (USPTO) on March 7, 2023 (Press release, Combined Therapeutics, MAR 13, 2023, View Source [SID1234628601]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This patent recognizes significant innovative research and development advances by Combined Therapeutics in the mRNA vaccine field and covers its vaccine compositions which include its proprietary mRNA MOPCTx (Multi-Organ Protection) technology to deliver viral or bacterial antigens in combination with a panel of molecular adjuvants. These mRNA-expressed antigens and adjuvants together are formulated in a delivery vehicle and can be used to develop both preventive as well as therapeutic vaccines against serious infectious diseases and cancer.

"We are still only at the beginning of where our mRNA platform can take us in our efforts to further optimize global mRNA vaccine safety and efficacy," said Romain Micol, M.D., MPH, Ph.D., the company’s president, chief executive officer and co-founder. "This recognition of our scientific advancements supports our development of next-generation mRNA medicines and strengthens our position as a leading innovator in vaccine technology."

As made evident by the recent pandemic, the world is increasingly in need of affordable, safe, and effective vaccines. CTx’s MOP technology offers a flexible mRNA platform that can be engineered to meet specific vaccine needs and demands. This platform allows vaccine antigen expression at the site of injection, where it is needed, while restricting expression in key organs such as the heart, liver, and kidney. Additionally, when combined with a molecular adjuvant, the CTx mRNA platform enhances several critical vaccine immunogenicity parameters including extending the duration of immunity, decreasing the needed vaccine dose and improving the protection of vulnerable populations.

On March 13, 2023 Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), reported that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023 (Press release, Liminal BioSciences, MAR 13, 2023, View Source,-2023 [SID1234628599]). Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To join the conference call without operator assistance, you may register and enter your phone number at https://bit.ly/3FeNJBk to receive an instant automated call back. You can also dial direct to be entered to the call by an Operator by dialing 416-764-8609 and 888-390-0605, using the following passcode: 77593817. An audio replay of the call will be available as of Thursday March 16, 2023 at 11:30 am (ET). The numbers to access the audio replay are 416-764-8677 and 1-888-390-0541 using the following password (593817 #). A live audio webcast of the conference call will be available by clicking here.